Insider Trading History of Hetherington Seth V

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Hetherington Seth V since 2006. The trader's CIK number is 1283841. At the time of the last reporting, Hetherington Seth V was the VP, Clinical Develop of Genocea Biosciences, Inc.. (stock ticker symbol GNCA). Also see all insider trading activities at Genocea Biosciences, Inc..

Note that in the past HETHERINGTON SETH V also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Genocea Biosciences, Inc. (GNCA) by Hetherington Seth V

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2016 GNCA 0 $0 0 $0 5,000 $10,100
2015 GNCA 0 $0 0 $0 10,000 $20,200
2014 GNCA 0 $0 0 $0 11,000 $22,220

Yearly summary of insider trading at Inhibitex Inc (INHX) by Hetherington Seth V

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2006 INHX 0 $0 8,305 $74,745 0 $0


Insider trading activities at 2 companies by Hetherington Seth V:

1. Genocea Biosciences, Inc. (GNCA)

2. Inhibitex Inc (INHX)

Table 1. Insider trading of Genocea Biosciences, Inc. (GNCA) by Hetherington Seth V

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2016-11-09 GNCA Option Ex 5,000 2.02 10,100
2015-12-11 GNCA Option Ex 5,000 2.02 10,100
2015-08-07 GNCA Option Ex 5,000 2.02 10,100
2014-08-18 GNCA Option Ex 11,000 2.02 22,220

Table 2. Insider trading of Inhibitex Inc (INHX) by Hetherington Seth V

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2006-01-10 INHX Sale 8,305 9.00 74,745

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hetherington Seth V (VP, Clinical Develop of Genocea Biosciences, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.